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Understanding and repurposing CRISPR-
mediated alternative splicing
Jordan L. Smith1, Haiwei Mou1 and Wen Xue1,2*
Abstract
Two new studies refine our understanding of CRISPR-
associated exon skipping and redefine its utility in
engineering alternative splicing.
Introduction
The simplest iteration of CRISPR/Cas9 (clustered regu-
larly interspaced short palindromic repeats/CRISPR-as-
sociated system 9) disrupts gene function by employing
one single guide RNA (sgRNA) to localize Cas9 to make
double-strand breaks (DSB) at a target genomic site.
Once a DSB has been created, the cell begins to repair
the DNA through non-homologous end joining (NHEJ),
resulting in the insertion or deletion of a small number
of nucleotides [1]. Previous surveys of CRISPR/Cas9
off-target effects suggested that the technology is rela-
tively precise, and thus positioned CRISPR/Cas9 as the
preferred system for genome editing in the laboratory
and potentially in the clinic. Multiple reports now sug-
gest, however, that CRISPR/Cas9 editing results in the
unintentional generation of alternatively spliced prod-
ucts, large genomic deletions, translocations and inver-
sions [2–5].
Here, we focus on the alternative splicing induced by
CRISPR/Cas9. Several groups have reported alternative
splicing following CRISPR/Cas9 editing with a sgRNA [2],
but the inciting event for exon skipping remains inconclu-
sive. Two recent publications have begun to both refine
our understanding of CRISPR-induced exon skipping and
redefine its utility. Specifically, Li and colleagues [6] set
out to provide new clarity on how CRISPR-associated
indels lead to exon skipping (Fig. 1a). Further, while alter-
native splicing is frequently considered an undesirable
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consequence of gene editing, Gapinske et al. [7] show that
CRISPR cytosine to thymidine base editors (CBEs) can be
repurposed for targeted splicing, adding to the repertoire
of tools available for programmable genome editing
(Fig. 1b).
How do CRISPR/Cas9 indels induce exon
skipping?
New results from Li et al. [6] suggest that CRISPR/Cas9
induces exon skipping only after the generation of a pre-
mature termination codon (PTC). The authors demon-
strate that the generation of a PTC following a
Cas9-induced DNA break results in nonsense-associated
alternative splicing (NAS) and the generation of alterna-
tive mRNA products.
The researchers used 22 CRISPR/Cas9 gene edited or
CBE rabbit lines. They sorted their mutated rabbit lines
by the type of indel: non-frameshift, missense, PTC, and
PTC in the first exon. Next, to determine whether the
type of indel influences the rate of CRISPR/Cas9-in-
duced exon skipping, they screened their 22 lines by
using reverse transcriptase polymerase chain reaction
(RT-PCR) to identify exon skipping events. No exon
skipping was found in either the non-frameshift rabbit
lines or the missense rabbit lines. In the rabbit lines with
PTC mutations in exons other than exon 1, however, the
researchers detected alternatively spliced mRNA. The
results of work by Li et al. [6] therefore suggest that
exon skipping occurs only following a PTC mutation, es-
tablishing a new rule for the prediction of when exon
skipping may occur. Specifically, exon skipping is not
dependent on the presence of DNA damage or an indel;
rather, a CRISPR indel can only result in exon skipping
if it generates a PTC in an exon other than exon 1
(Fig. 1a).
Purposeful alternative splicing with CRISPR-SKIP
While exon skipping has most often been regarded as an
off-target effect that must be mitigated, previous reports
have recognized the potential use of CRISPR/Cas9
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alternative splicing for disease correction [2]. Targetable
exon exclusion strategies have already shown potential
therapeutic benefit in many monogenic diseases, including
Duchenne’s muscular dystrophy, and Huntington’s disease
[8]. Recent work by Gapinske et al. [7] harnesses the
unique precision of CBEs to create a new biomedical tool
for programmable gene splicing, termed CRISPR-SKIP [7].
Because nearly every intron ends with a guanine, the
authors hypothesized that CBEs may be used to disrupt
the highly conserved splice acceptor consensus sequence
for the exclusion of the following exon. Cystine to thy-
midine (C > T) CBEs have been shown previously to
mutate guanine sites successfully by converting the com-
plementary base, cystine [9, 10]. To test their hypothesis,
Gapinske et al. [7] employed a C > T SpCas9 Base editor,
composed of the APOBEC1 cytidine deaminase, the
SpCas9-D10A nickase, and the PBS1 uracil glycolase in-
hibitor (Fig. 1b).
For simple detection of exon skipping, Gapinske et al.
[7] selected exon 7 of RELA as a test locus because its
length, a multiple of three, limits the likelihood that base
editing would create a frameshift mutation and trigger
nonsense-mediated decay. In conjunction with exon 7 of
RELA, the authors also targeted the splice acceptor of
exon 5 in PIK3CA. Using deep sequencing, the authors
found a base-editing rate of 6.26% G > C in RELA and
26.38% in PI3KCA. These percentages corresponded to
an exon skipping rate of 15.46% in RELA and 37.5% in
PI3KCA. Surprisingly, at the exon 5 PI3KCA splice ac-
ceptor site, the authors also detected G > C (14.66%),
G > T (2.58%), and a G > A (10.34%) modifications more
than 20-nucleotides outside the CBE target range.
Gapinske et al. [7] also compared the rate of exon
skipping generated by CRISPR-SKIP to that of skip-
ping induced by CRISPR/Cas9 following a DSB, as
described by Li et al. [6]. With sgRNAs that were not
targeted to the splice acceptor, CRISPR/Cas9 induced
either an equivalent number of or fewer exon skip-
ping events than CRISPR-SKIP. When the authors
used the same sgRNAs targeted to the splice acceptor
for both CRISPR-SKIP and CRISPR/Cas9, they found
that CRISPR/Cas9 was more effective at inducing
exon skipping at three of the five targets, whereas
CRISPR-SKIP was more effective at the other two.
Further, the authors sought to expand CRISPR-SKIP’s
utility by eliminating its dependence on the presence
of an NGG protospacer adjacent motif (PAM) 12–
17 bp from the target cytidine. They successfully
demonstrated that CBE with different Cas9 scaffolds,
including SpCas9-VQR-BE3 with NGA PAM and
SaCas9-KKH-BE3 with NNNRRT PAM, can induce
targeted exon skipping.
Finally, to ease the burden of identifying suitable tran-
scripts for CRISPR-SKIP base editing, Gapinske et al. [7]
developed a web-based software tool that allows re-
searchers to identify appropriate sgRNAs for a desired
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Fig. 1 Mechanisms of CRISPR-induced exon skipping. a From Li et al. [6], CRISPR/Cas9 induces exon skipping only with the generation of a premature
termination codon (PTC) in an exon other than exon 1. b From Gapinske et al. [7], CRISPR-SKIP repurposes the C > T SpCas9 Base editor, composed of
the APOBEC1 cytidine deaminase, the SpCas9-D10A nickase, and the PBS1 uracil glycolase inhibitor (UGI), to mutate splice acceptor sites and thus to
induce programmable exon skipping. PAM, Protospacer adjacent motif; sgRNA, single guide RNA
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target, incorporates the various CBEs and their effi-
ciency, and generates an off-target score.
Skipping forward
As CRISPR/Cas9 gene editing accelerates from the
bench to the clinic, understanding and perhaps exploit-
ing the unintentional consequences, including exon skip-
ping, translocations, inversion, and deletions, will take
center stage. Two recent publications from Li et al. [6]
and Gapinske et al. [7] refine our understanding of how
CRISPR/Cas9 indels induce exon skipping, and further
broaden the CRISPR tool-kit to include programmable
exon skipping.
Li et al. [6] sheds new light on how CRISPR/Cas9 gene
inactivation inadvertently results in exon skipping. The
authors’ finding that only PTC mutations induce exon
skipping narrows the hunt for the inciting event of exon
skipping, limiting the likelihood that DNA damage or
the indel itself have causative roles. These authors sug-
gest that their finding further supports the hypothesis of
a ‘nuclear scanning mechanism’ that enables the cell to
identify pre-mRNAs with PTCs and shuttles these tran-
scripts through nonsense-associated alternative splicing.
We do not yet know how the cell identifies these tran-
scripts, and why the location of the PTC determines
whether the transcript undergoes nonsense-mediated
decay or nonsense-associated alternative splicing. Fur-
ther, the role of cis-regulatory elements, specifically ex-
onic splicing silencers, remains elusive. In Li et al.’s
study, several missense rabbit lines had disruption of ex-
onic regulatory elements, but only premature PTC lines
resulted in exon skipping. Li et al. [6] provides re-
searchers with a new guideline to screen for the pres-
ence of alternative mRNA products following CRISPR/
Cas9 editing. Specifically, it’s advisable to sequence
through your indel, and if it is a predicted PTC, run a
RT-PCR to screen for the presence of alternative mRNA
products.
Although exon skipping is often viewed as an unin-
tended consequence of CRISPR/Cas9 gene editing,
Gapinske et al. [7] harnessed CBEs in CRISPR-SKIP to
achieve intentional programmable alternative splicing.
CRISPR-SKIP has potential broad utility in both biotech-
nology and the clinic. Gapinske et al. [7] estimate that
118,089 out of 187,636 inner exons in protein-coding
genes are targetable. CRISPR-SKIP could be harnessed
as a therapeutic tool to address genetic disease by direct-
ing the expression of specific mRNA transcripts. In
addition, unlike other exon skipping platforms,
CRISPR-SKIP induces stable changes and thus increases
the likelihood that a single treatment may be therapeutic
for patients. Perhaps the most critical advantage of
CRISPR-SKIP over other exon-skipping technologies, in-
cluding canonical CRISPR/Cas9, is that it does not
introduce high-levels of DSBs into the genome, reducing
the probabilities of large deletions, translocations and in-
versions observed with Cas9 [2, 3].
The two articles highlighted here generate further
questions around critical gaps in our understanding of
how and when splicing occurs in CRISPR-edited sys-
tems. For example, Gapinske and colleagues [7] found
that they were able to edit approximately 77% of the
splice acceptors that were targeted, but only 50% of sub-
sequent exons were skipped. Missed exon skipping may
be the result of cryptic splice acceptor sites, incomplete
understanding of intron-exon biology, or the need for
optimization of base-editing technologies.
Taken together, these two publications provide a crit-
ical framework for understanding the mechanism and
utility of CRISPR-induced exon skipping.
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